Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.75 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.75 |
| ▸ | CDK9 | P50750 | 8/20 | 0.75 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.75 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.75 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.71 |
| ▸ | CCNK | O75909 | 9/20 | 0.71 |
| ▸ | CDK12 | Q9NYV4 | 9/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.71 |
| ▸ | CDK1 | P06493 | 7/20 | 0.71 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.71 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.71 |
| ▸ | CDK7 | P50613 | 6/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.71 |
| ▸ | CCNH | P51946 | 4/20 | 0.71 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.71 |
| ▸ | CDK4 | P11802 | 3/20 | 0.71 |
| ▸ | CCND1 | P24385 | 3/20 | 0.71 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.61 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19139043 | 1.00 | CDK2 (0.75) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL19111955 | 1.00 | CDK2 (0.75) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL19112176 | 0.91 | CDK2 (0.61) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL23961653 | 0.91 | CDK2 (0.69) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL23993156 | 0.90 | CDK2 (0.60) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL29684386 | 0.89 | CDK1 (0.67) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL23752348 | 0.89 | CDK1 (0.67) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL19111944 | 0.89 | CDK1 (0.67) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL22022251 | 0.88 | CDK2 (0.72) | CDK2CCNA2CDK9CCNA1CCNT1 | |
| SCHEMBL23992724 | 0.85 | CDK1 (0.57) | CDK2CCNA2CDK9CCNA1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2022-10-18 | — | — | US | disclosed |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2020-11-12 | — | — | US | disclosed |
| EP-2664619-B1 | Purine derivatives as tools for screening anti-Alzheimer compounds | MANROS THERAPEUTICS (FR) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | ADORA1, OXGR1, ADORA2A | CDK2 1842/4885CCNA2 1833/4885CDK9 2449/4885 |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | TPMT, ADORA2A, PNP | CDK2 3765/4885CCNA2 3783/4885CDK9 3454/4885 |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | TPMT, ADORA2A, PNP | CDK2 3765/4885CCNA2 3783/4885CDK9 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.